October 26, 2016
The Ninth Circuit on Wednesday revived a proposed class action against Arena Pharmaceuticals alleging the company lied to shareholders about tests for a diet drug, finding that even though the drug was later approved, the company shouldn't have told shareholders testing was going smoothly when it wasn't.